KRAS Engages AGO2 to Enhance Cellular Transformation
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Oncogenic mutations in RAS provide a compelling yet intractable therapeutic target. Using co-immunoprecipitation mass spectrometry, we uncovered an interaction between RAS and Argonaute 2 (AGO2). Endogenously, RAS and AGO2 co-sediment and co-localize in the endoplasmic reticulum. The AGO2 N-terminal domain directly binds the Switch II region of KRAS, agnostic of nucleotide (GDP/GTP) binding. Functionally, AGO2 knockdown attenuates cell proliferation in mutant KRAS-dependent cells and AGO2 overexpression enhances KRAS(G12V)-mediated transformation. Using AGO2-/- cells, we demonstrate that the RAS-AGO2 interaction is required for maximal mutant KRAS expression and cellular transformation. Mechanistically, oncogenic KRAS attenuates AGO2-mediated gene silencing. Overall, the functional interaction with AGO2 extends KRAS function beyond its canonical role in signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“In recent years, there is a renewed interest in targeting RAS to alter its status from an undruggable to druggable candidate (Burns et al., 2014; Ostrem et al., 2013; Spiegel et al., 2014; Stephen et al., 2014; Sun et al., 2012).”
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Constitutively elevated levels of Ras-GTP aberrantly activate downstream effector pathways that promote neoplastic transformation (Karnoub and Weinberg, 2008; Shaw and Cantley, 2006; Trahey and McCormick, 1987).”
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“Approximately one-third of human cancers harbor an oncogenic mutation in HRAS, KRAS, or NRAS (Balmain and Pragnell , 1983; Karnoub and Weinberg, 2008; Pylayeva-Gupta et al., 2011).”
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 9×
“Peptide fragments deduced from MS analyses spectral counts revealed robust detection of the bait protein (RAS) in all the 12 C B 1 1 1 1 1 R 1 1 Unique peptides Shared peptides KRAS NRAS HRAS AGO1 AGO2 AGO3 AGO4 189 189 189 860 859 857 859 A D MIA PaCa-2, H2009, H727, HPNE, BXPC3, KRAS KRAS Ctrl RAS”
InfluentialA Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 2×
“Despite extensive characterization of the Ras/GAP molecular switch(es) and downstream signaling axes, therapeutic targeting of RAS-driven cancers remains elusive (Baines et al., 2011; Downward, 2003; Stephen et al., 2014).”
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490 · cited 1×
“In recent years, there is a renewed interest in targeting RAS to alter its status from an undruggable to druggable candidate (Burns et al., 2014; Ostrem et al., 2013; Spiegel et al., 2014; Stephen et al., 2014; Sun et al., 2012).”
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347 · cited 2×
“We also performed the coIP analysis in genetically engineered ''RASless'' mouse embryonic fibroblast cells (Drosten et al., 2010) and failed to detect this interaction upon ablation of KRAS expression (Figure S1I), further establishing the specificity of the RAS-AGO2 interaction.”
Cited by
KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes
McKenzie, A. J., Hoshino, D., Hong, N. H., Cha, D. J., Franklin, J. L., Coffey, R. J., Patton, J. G., & Weaver, A. M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.085 · Cited by 423
The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2
Kovalski, J. R., Bhaduri, A., Zehnder, A. M., Neela, P. H., Che, Y., Wozniak, G. G., & Khavari, P. A. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.001 · Cited by 154
“Traditional mass spectrometry studies using affinity purification approaches require stable protein interactions in cell extracts (Goldfinger et al., 2007; Shankar et al., 2016).”
BackgroundResolving subcellular miRNA trafficking and turnover at single-molecule resolution
Pitchiaya, S., Heinicke, L. A., Park, J. I., Cameron, E. L., & Walter, N. G. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.075 · Cited by 98
Self-citationGebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26526-y · Cited by 49
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
Method
Metadata
- Authors
- Shankar, S., Pitchiaya, S., Malik, R., Kothari, V., Hosono, Y., Yocum, A. K., Gundlapalli, H., White, Y., Firestone, A., Cao, X., Dhanasekaran, S. M., Stuckey, J. A., Bollag, G., Shannon, K., Walter, N. G., Kumar-Sinha, C., & Chinnaiyan, A. M.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 14
- Issue
- 6
- Pages
- 1448-1461
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2271216541
- Cited by
- 46
- References
- 15
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.